BioCentury | Mar 25, 2019
Distillery Therapeutics

Inhibiting RAR for retinitis pigmentosa

...with no treatment. Next steps could include testing RAR inhibitors in other models of retinitis. Io Therapeutics inc....
BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer

...Co. Ltd. market Targretin bexarotene, an oral RXR agonist, for cutaneous T cell lymphoma (CTCL). Io Therapeutics Inc....
BioCentury | Oct 27, 2016
Distillery Therapeutics

Cancer

...KGaA have the RXR agonist BBI-3000 oral in preclinical testing to treat psoriasis and acne. Io Therapeutics Inc....
BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

...mAb Biogen Inc. (NASDAQ:BIIB) Antibody Phase II IRX4204 Retinoid X receptor (RXR) Selective pan-RXR agonist Io Therapeutics Inc....
BioCentury | Feb 25, 2016
Strategy

Changing the channel

...respond to requests for comment. At least one other company is developing an RXR agonist: Io Therapeutics Inc....
...GBSI), Washington, D.C. Harvard Medical School, Boston, Mass. Howard Hughes Medical Institute, Chevy Chase, Md. Io Therapeutics Inc....
BioCentury | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

...the oral RARG and RXR agonist peretinoin in Phase III testing to treat liver cancer. Io Therapeutics Inc....
BioCentury | Dec 12, 2013
Distillery Therapeutics

Indication: Hematology

...fibrosis. Next steps could include testing RAR antagonists in additional mouse models of myeloproliferative disease. Io Therapeutics Inc....
BioCentury | Mar 11, 2013
Company News

Io Therapeutics, Michael J. Fox Foundation For Parkinson's Research deal

...that the foundation will fund preclinical development of the company's IRX4204 to treat Parkinson's disease. Io Therapeutics...
...and Alzheimer's disease (AD), as well as Phase II testing to treat advanced prostate cancer. Io Therapeutics Inc....
BioCentury | Oct 1, 2012
Clinical News

Io Therapeutics preclinical data

...RXR ) agonist is also in Phase II testing to treat advanced prostate cancer. Io Therapeutics Inc....
BioCentury | Oct 17, 2011
Clinical News

IRX4204: Phase II started

...Io began a Phase II trial to evaluate IRX4204 in patients. Io Therapeutics Inc. , Santa Ana, Calif...
Items per page:
1 - 10 of 10
BioCentury | Mar 25, 2019
Distillery Therapeutics

Inhibiting RAR for retinitis pigmentosa

...with no treatment. Next steps could include testing RAR inhibitors in other models of retinitis. Io Therapeutics inc....
BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer

...Co. Ltd. market Targretin bexarotene, an oral RXR agonist, for cutaneous T cell lymphoma (CTCL). Io Therapeutics Inc....
BioCentury | Oct 27, 2016
Distillery Therapeutics

Cancer

...KGaA have the RXR agonist BBI-3000 oral in preclinical testing to treat psoriasis and acne. Io Therapeutics Inc....
BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

...mAb Biogen Inc. (NASDAQ:BIIB) Antibody Phase II IRX4204 Retinoid X receptor (RXR) Selective pan-RXR agonist Io Therapeutics Inc....
BioCentury | Feb 25, 2016
Strategy

Changing the channel

...respond to requests for comment. At least one other company is developing an RXR agonist: Io Therapeutics Inc....
...GBSI), Washington, D.C. Harvard Medical School, Boston, Mass. Howard Hughes Medical Institute, Chevy Chase, Md. Io Therapeutics Inc....
BioCentury | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

...the oral RARG and RXR agonist peretinoin in Phase III testing to treat liver cancer. Io Therapeutics Inc....
BioCentury | Dec 12, 2013
Distillery Therapeutics

Indication: Hematology

...fibrosis. Next steps could include testing RAR antagonists in additional mouse models of myeloproliferative disease. Io Therapeutics Inc....
BioCentury | Mar 11, 2013
Company News

Io Therapeutics, Michael J. Fox Foundation For Parkinson's Research deal

...that the foundation will fund preclinical development of the company's IRX4204 to treat Parkinson's disease. Io Therapeutics...
...and Alzheimer's disease (AD), as well as Phase II testing to treat advanced prostate cancer. Io Therapeutics Inc....
BioCentury | Oct 1, 2012
Clinical News

Io Therapeutics preclinical data

...RXR ) agonist is also in Phase II testing to treat advanced prostate cancer. Io Therapeutics Inc....
BioCentury | Oct 17, 2011
Clinical News

IRX4204: Phase II started

...Io began a Phase II trial to evaluate IRX4204 in patients. Io Therapeutics Inc. , Santa Ana, Calif...
Items per page:
1 - 10 of 10